Founded in 2015, Zetagen has developed a unique molecular pathway technology called ZetaMet™, which aims to suspend cancer, alleviate pain, and regenerate bone. The company has successfully completed preclinical trials for its drug-eluting implant technology and is preparing for its first human clinical trial in Q4 2021. In addition to ZetaMet™, Zetagen's pipeline includes other oncologic treatments for Skeletal Related Events (SREs) and ancillary osteologic treatments. The company is supported by Series A funding, private and angel investors, and research grants from the NIH. Zetagen's products have the potential to transform the treatment of bone-related injuries, procedures, and diseases, delivering better outcomes for patients, doctors, and payors.